Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
秉鸿资本 (“BROADHI CAPITAL”) is an established Chinese private equity and venture capital investment management firm founded in 2010. It manages over ten funds and has offices in Beijing, Shanghai, Shenzhen, Henan, and Qingdao. The firm focuses on growth-stage and pre–IPO companies across China with an emphasis on value investing. It does not control portfolio companies but provides strategic support to help them grow and prepare for public listing. Its investments span various industries that align with national industrial policy; some portfolio companies are in the healthcare/life sciences sector. The company has received industry recognition as one of China’s top private equity institutions. It does not itself develop drugs or medical products. Example of portfolio company in life sciences invested by 秉鸿资本: 弈柯莱生物(Ecolab Biotech)— recognized as a high-potential enterprise. No direct clinical results or pipeline as it acts as an investor.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 秉鸿资本.